Jazz Pharmaceuticals' Ziihera Shows Superior Overall Survival in HER2+ GEA Trial
Event summary
- Ziihera (zanidatamab-hrii) plus chemotherapy demonstrated statistically significant overall survival (OS) benefits over trastuzumab plus chemotherapy in the Phase 3 HERIZON-GEA-01 trial for first-line HER2+ advanced gastroesophageal adenocarcinoma (GEA).
- The OS hazard ratio improved compared to the first interim analysis, reinforcing Ziihera's superiority over trastuzumab.
- Ziihera plus tislelizumab and chemotherapy showed further improved OS hazard ratio with longer follow-up.
- FDA approved Ziihera for first-line HER2+ GEA on August 25, 2026.
- Jazz Pharmaceuticals plans to present these data at a major medical meeting in Q4 2026.
The big picture
Jazz Pharmaceuticals' Ziihera is positioning itself as the new benchmark in HER2-targeted therapy for first-line HER2+ advanced GEA, replacing trastuzumab. The statistically significant OS benefits demonstrated in the HERIZON-GEA-01 trial reinforce Ziihera's potential to extend survival beyond current standards. This strategic shift could reshape the treatment paradigm for HER2+ GEA, a cancer with high morbidity and mortality.
What we're watching
- Market Adoption
- The pace at which Ziihera plus tislelizumab and chemotherapy becomes the new standard of care in HER2+ first-line GEA.
- Regulatory Expansion
- Whether Jazz Pharmaceuticals can secure additional global health authority approvals based on these updated results.
- Competitive Positioning
- How these results will impact the competitive landscape for HER2-targeted therapies in GEA.
Related topics